SLC8B1 and familial dilated cardiomyopathy: Advanced DCM (decompensated phase): Inhibiting mPTP opening (e.g., CypD-targeted agents) or enhancing Ca2+ efflux [e.g., NCLX activators (92)] could attenuate cardiomyocyte loss.